EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos

Filippo Carletti, Flavia Tamborino, Alexandru Turcan, Valerio Santarelli, Fabio Maria Valenzi, Luca Alfredo Morgantini, Hakan Bahadir Haberal, Fabrizio Dal Moro, Simone Crivellaro

European Urology Focus · 2026

DOI: 10.1016/j.euf.2026.01.003 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Urology Focus, 2026. Verfasst von Filippo Carletti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Illinois at Chicago, Chicago, IL, USA; Urologic Unit, Department of Surgery, Oncology and Gastroenterology, Univ…. Hauptthemen laut MEDLINE: Prostatic Hyperplasia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Surgical treatments for benign prostatic hyperplasia (BPH) have expanded with the diffusion of minimally invasive surgical treatments (MISTs), but concerns persist regarding their long-term durability. This study aimed to provide a comprehensive, real-world description of current treatment trends, retreatment rates, and medication reinitiation up to 5 yr following MISTs and traditional procedures. METHODS: This observational retrospective fixed-cohort study was conducted using Epic Cosmos, including data of 6 450 295 patients and 420 611 procedures between 2014 and 2024. The primary outcome was procedural trend; the secondary outcomes were surgical retreatment and medication reinitiation. Analyses were descriptive and unadjusted for potential confounders due to the aggregated nature of the dataset. KEY FINDINGS AND LIMITATIONS: At 5 yr, retreatment rates were higher after prostatic urethral lift (PUL; 16%), transurethral needle ablation of the prostate (15%), transurethral microwave thermotherapy (17%), and Rezūm (14%), and lower after holmium laser enucleation of the prostate (HoLEP)/thulium laser enucleation of the prostate (ThuLEP; 4.4%) and simple prostatectomy (1.2%) when compared with transurethral resection of the prostate (TURP; 7.1%). Medication reinitiation at 5 yr was more common after MISTs (PUL: 21% α-blockers, 25% 5α-reductase inhibitors [5-ARIs], and 27% overactive bladder [OAB] drugs; all p 0.99) and lower following traditional procedures, including HoLEP/ThuLEP-11% α-blockers (p < 0.001), 12% 5-ARIs (p < 0.001), and 21% OAB drugs (p = 0.3), and simple prostatectomy-5.4% α-blockers (p < 0.001), 6.5% 5-ARIs (p < 0.001), and 9.4% OAB drugs (p < 0.001), when compared with TURP (15% α-blockers, 17% 5-ARIs, and 23% OAB drugs). Limitations include the use of aggregated electronic health record data subject to coding errors and the inability to adjust for clinical variables such as prostate size and symptom severity. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this large, real-world cohort, anatomical procedures such as HoLEP, ThuLEP, and simple prostatectomy were associated with the lowest long-term rates of retreatment and medication restart, whereas higher rates were observed with MISTs, particularly PUL and Rezūm. TURP remained the most performed procedure. As the use of MISTs declines after its initial uptake, future studies should clarify which patient characteristics may underlie these observed differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaMaleHumansRetrospective StudiesRetreatmentAgedMiddle AgedTransurethral Resection of ProstateTreatment OutcomeMinimally Invasive Surgical ProceduresTime Factors

Stichwörter der Autor:innen

AquablationBenign prostatic hyperplasiaHolmium laser enucleation of the prostateMinimally invasive surgical treatmentsProstatic urethral liftRetreatment ratesRezūmThulium laser enucleation of the prostateTransurethral resection of the prostateTrends

Autor:innen und Institutionen

  • Department of Urology, University of Illinois at Chicago, Chicago, IL, USA; Urologic Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy. Electronic address: filippo.carletti@a…
  • Department of Urology, University of Illinois at Chicago, Chicago, IL, USA.
  • Urologic Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.

Zitieren

APA

Carletti, F., Tamborino, F., Turcan, A., Santarelli, V., Valenzi, F. M., Morgantini, L. A., Haberal, H. B., Dal Moro, F., & Crivellaro, S. (2026). Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos. European Urology Focus. https://doi.org/10.1016/j.euf.2026.01.003

Vancouver

Carletti F, Tamborino F, Turcan A, Santarelli V, Valenzi FM, Morgantini LA, et al. Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos. European Urology Focus. 2026. doi:10.1016/j.euf.2026.01.003

BibTeX
@article{Carletti2026,
  author = {Carletti, Filippo and Tamborino, Flavia and Turcan, Alexandru and Santarelli, Valerio and Valenzi, Fabio Maria and Morgantini, Luca Alfredo and Haberal, Hakan Bahadir and Dal Moro, Fabrizio and Crivellaro, Simone},
  title = {Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos},
  journal = {European Urology Focus},
  year = {2026},
  doi = {10.1016/j.euf.2026.01.003}
}
Kostenlos starten →